T1	Participants 50 78	chronic lymphocytic leukemia
T2	Participants 175 229	patient outcomes in chronic lymphocytic leukemia (CLL)
T3	Participants 277 374	patients who will benefit from immunochemotherapy over chemotherapy alone has not been determined
T4	Participants 388 518	genome-wide expression of 300 pretreatment specimens from a subset of 552 patients in REACH, a study of FC or R-FC in relapsed CLL
T5	Participants 520 648	An independent test set was derived from 282 pretreatment specimens from CLL8, a study of FC or R-FC in treatment-na√Øve patients
